Cargando…

Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

This study assessed the immunogenicity and safety of the BNT162b2 mRNA vaccine in lung cancer patients receiving anticancer treatment. We enrolled lung cancer patients receiving anticancer treatment and non-cancer patients; all participants were fully vaccinated with the BNT162b2 vaccine. Blood samp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakashima, Kei, Ishida, Masayuki, Matsui, Hiroki, Yoshida, Chihiro, Nagai, Tatsuya, Shiraga, Minoru, Nakaoka, Hiroshi, Otsuka, Yoshihito, Nakagama, Yu, Kaku, Natsuko, Nitahara, Yuko, Kido, Yasutoshi, Hirota, Yoshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronavirus – Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746471/ https://www.ncbi.nlm.nih.gov/pubmed/36369871 http://dx.doi.org/10.1080/21645515.2022.2140549

Ejemplares similares

A Dual-Antigen SARS-CoV-2 Serological Assay Reflects Antibody Avidity
por: Nakagama, Yu, et al.
Publicado: (2022)

Age-adjusted impact of prior COVID-19 on SARS-CoV-2 mRNA vaccine response
por: Nakagama, Sachie, et al.
Publicado: (2023)

Serological Testing Reveals the Hidden COVID-19 Burden among Health Care Workers Experiencing a SARS-CoV-2 Nosocomial Outbreak
por: Nakagama, Yu, et al.
Publicado: (2021)

Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies
por: Nakagama, Yu, et al.
Publicado: (2022)

Longitudinal ventilatory ratio monitoring for COVID-19: its potential in predicting severity and assessing treatment response
por: Kaku, Natsuko, et al.
Publicado: (2021)

High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients
por: Nitahara, Yuko, et al.
Publicado: (2021)

Cumulative seroprevalence among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador, Central America
por: Nakagama, Yu, et al.
Publicado: (2022)

Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination
por: Hara, Megumi, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Inflammatory cardiomyopathy of possibly overlapping aetiology: a case posing treatment dilemma and potential association
por: Nakagama, Shun, et al.
Publicado: (2021)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
por: Yu, Michael Kwan Leung, et al.
Publicado: (2023)

Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan
por: Matsuura, Tomoka, et al.
Publicado: (2022)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
por: Yassini, Patrick, et al.
Publicado: (2023)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants
por: Fan, Feng, et al.
Publicado: (2023)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
por: Thuluva, Subhash, et al.
Publicado: (2023)

Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity
por: Nakagama, Yu, et al.
Publicado: (2022)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2023)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
por: Sahay, Rima R., et al.
Publicado: (2022)

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study
por: Yan, Vincent Ka Chun, et al.
Publicado: (2022)

The interplay between emerging human coronavirus infections and autophagy
por: Zhao, Zhenyu, et al.
Publicado: (2021)

Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
por: Criscuolo, Elena, et al.
Publicado: (2021)

COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue
por: Yongzhi, Xi
Publicado: (2021)

Isolation of SARS-CoV-2 strains carrying a nucleotide mutation, leading to a stop codon in the ORF 6 protein
por: Delbue, Serena, et al.
Publicado: (2021)

Saliva viral load better correlates with clinical and immunological profiles in children with coronavirus disease 2019
por: Chua, Gilbert T., et al.
Publicado: (2021)

Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
por: Ye, Zi-Wei, et al.
Publicado: (2021)

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
por: Hu, Yanmei, et al.
Publicado: (2021)

Novel dual multiplex real-time RT-PCR assays for the rapid detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus using the BD MAX open system
por: Chung, Hsing-Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ki15m1r3ukjpdt9pvra8fos4tk